REPLY
Reply, an international group specialised in creating new business models enabled by AI and Digital Media, introduces the jury that will be tasked with evaluating and selecting the best short films for the Reply AI Film Festival, an international competition open to all creatives eager to engage in creating a short film using AI tools.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240618976841/en/
Reply presents the inaugural Reply AI Film Festival, an international competition where Artificial Intelligence (AI) serves not only as a catalyst for innovation in the realm of creative storytelling but also as a tool for fostering inclusivity among younger generations in video and film production. (Photo: Reply)
Judging the works submitted in the four competition categories - Narratives, Pilots, Documentaries, and Experimental - will be: Adam Kulick, producer of successful films such as Twilight, Wuthering Heights, and The Iron Lady, as well as a Sloan Fellow at Stanford University specialising in Generative AI; Caleb & Shelby Ward, co-founders of Curious Refuge, the first online community dedicated to directors using AI in their creations; Denise Negri, a journalist from SkyTg24 and Sky Arte, known for covering prestigious film events like the Academy Awards, Cannes Film Festival, and Venice Film Festival. Also participating are Filippo Rizzante, Chief Technology Officer at Reply; Flavio Natalia, director of Ciak and ciakmagazine.it, and an author and journalist for Ansa, Rai, and Sky; as well as the Canadian duo Vallée Duhamel, comprised of Julien Vallée and Eve Duhamel, who create unique short films for international brands using captivating images and videos that blend playful approaches with experimentation in new technologies such as artificial intelligence. Monica Riccioni, Chief Executive Officer of Think Cattleya, an advertising agency that has collaborated with numerous international directors and created campaigns for renowned global brands; Paul Trillo, a director and video artist known for his conceptual and visually inventive films, integrating new tools like AI with traditional techniques; and Rob Minkoff, co-director of The Lion King (1994) and animator and director of numerous films including Stuart Little, The Haunted Mansion, and Mr. Peabody & Sherman.
The jury will select the short films submitted to the competition via the platform aiff.reply.com by July 1, 2024, interpreting the theme of this first edition of the festival: Synthetic Stories, Human Hearts, a title that celebrates the convergence of human talent and artificial intelligence. In doing so, they will follow three main criteria: creativity, which refers to the innovative scope of cinematic language; craftsmanship, meaning the overall quality and value of the short film's production; and the impact of artificial intelligence, assessing how AI tools have contributed to one or more aspects of its creation.
Adam Kulick commented, "GenAI's integration into filmmaking processes opens up a new era of creativity and justifiable concerns. I'm hopeful that the fusion of human ingenuity and these rapidly evolving technologies produces groundbreaking work and new opportunities for the filmmaking community."
"We believe AI is going to act as a creative assistant in every part of the filmmaking pipeline. It’s going to allow for new stories to be told, it’s going to democratise the filmmaking industry and support filmmakers all around the world in telling their stories." said Caleb & Shelby Ward.
"AI is an increasingly valuable ally of creativity. We are truly delighted that such high-calibre figures in the film world have joined our initiative: a space to test AI as an ally of human creativity, but also an opportunity for young talents to immerse themselves in new technologies, acquire advanced skills, and bring new narratives to life," said Filippo Rizzante.
"I have always supported the potential of AI and believe that the combination of human and technological talent is not only possible but also enriches our work. This added value is something we at Think Cattleya greatly value and I am certain I will witness it during the screening of the short films in this competition," said Monica Riccioni.
"Specifically, AI's role should always be to assist the creatives, producers and crew working in film and not to replace them. It should not be used as a crutch or a shortcut for the creatively bankrupt. This is an opportunity for independent filmmakers to think out of the box and for smaller productions to create better, bolder and stranger films." confirmed Paul Trillo.
The ten best short films will be presented at a special premiere event organised by Reply, together with Mastercard, which has always been close to the world of cinema, connecting fans, performers and advocates to their passion. The event will take place during the days of the 81st Venice International Film Festival where the three overall winners will be announced.
To learn more about the Reply AI Film Festival, visit aiff.reply.com.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialised companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of big data, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618976841/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
Perma-Pipe International Holdings, Inc. Announces Third Quarter Financial Results23.12.2024 18:43:00 CET | Press release
The Company generated net sales of $41.6 million for the quarter and $113.4 million year-to-dateIncome before income taxes of $5.1 million for the quarter and $13.2 million year-to-dateBacklog of $114.2 million at October 31, 2024, compared to $68.5 million at January 31, 2024 Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the second quarter and fiscal year-to-date period ended October 31, 2024. "Net sales for the third quarter were $41.6 million, a decrease of $4.1 million, as compared to the same quarter last year. Net income attributable to common stock of $2.5 million was an increase of $0.5 million, or 29%, compared to $1.9 million in the third quarter of 2023. For the nine months ended October 31, 2024, net sales of $113.4 million represent an increase of 3% compared to the nine months ended October 31, 2023. The net income attributable to common stock of $7.2 million was an increase of $5.4 million, or 294%, compared to net income at
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom